Pancreatic Cancer

>

Latest News

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.
mFOLFIRINOX/S-IROX Does Not Show Superiority to SOC in Pancreatic Cancer

August 22nd 2025

After the predictive probability of achieving superiority with mFOLFIRINOX or S-IROX was less than 1%, the trial was terminated due to futility.

Previously, TTFields was granted approval by the FDA in previously treated metastatic NSCLC.
Developer Submits Premarket Approval Application for TTFields in Pancreatic Cancer

August 21st 2025

Induction chemotherapy may allow investigators to biologically select patients with a favorable prognosis who benefit most from chemoradiotherapy.
Chemoradiation May Convert Unresectable Pancreatic Cancers for Resection

August 20th 2025

The retrospective study is the largest to evaluate the relationship between dose-averaged LET profiles and local control after CIRT for pancreatic cancer.
Low Dose-Averaged LET Exhibits Poor Local Control in Pancreatic Cancer

August 20th 2025

Data from the PANOVA-3 trial may support the concomitant use of TTFields plus standard of care in solid tumors across different therapeutic settings.
TTFields Combo Shows Meaningful Benefits in Pancreatic Adenocarcinoma

August 7th 2025

Latest CME Events & Activities

More News